https://new.semnurpharma.com/2024/08/02/gigi-deguzman/2025-10-02T10:00:56-07:00https://new.semnurpharma.com/2014/05/16/tie50-awards-program-2014/2024-09-03T12:15:59-07:00https://new.semnurpharma.com/2016/08/15/scintilla-pharmaceuticals-inc-subsidiary-sorrento-therapeutics-inc-acquire-semnur-pharmaceuticals-inc-deepen-pain-management-pipeline/2024-09-03T12:15:25-07:00https://new.semnurpharma.com/2017/06/26/semnur-pharmaceuticals-inc-announces-successful-phase-1-2-trial-patients-radicular-pain-lead-product-sp-102/2024-09-03T12:15:06-07:00https://new.semnurpharma.com/2018/01/07/semnur-pharmaceuticals-begins-pivotal-phase-3-trial-sp-102-patients-lumbar-radicular-painsciatica/2024-09-03T12:13:40-07:00https://new.semnurpharma.com/2019/03/22/sorrento-therapeutics-announces-merger-scilex-semnur-create-global-leader-non-opioid-pain-management/2024-09-02T22:30:49-07:00https://new.semnurpharma.com/2024/08/05/dmitri-lissin/2025-09-04T11:37:48-07:00https://new.semnurpharma.com/2024/08/06/stephen-ma/2025-10-02T10:04:16-07:00https://new.semnurpharma.com/2019/03/27/scilex-holding-subsidiary-sorrento-therapeutics-announces-phase-2-trial-results-leading-sp-102-program/2024-09-03T12:13:10-07:00https://new.semnurpharma.com/2024/08/04/suketu-desai/2025-09-04T11:38:42-07:00https://new.semnurpharma.com/2019/04/15/scilex-semnur-corporate-presentation/2024-08-01T16:00:59-07:00https://new.semnurpharma.com/2024/07/02/letter-of-intent-for-a-proposed-business-combination/2024-08-13T10:21:15-07:00https://new.semnurpharma.com/2024/06/14/a-randomized-placebo-controlled-trial-of-long-acting-dexamethasone-viscous-gel-delivered-by-transforaminal-injection-for-lumbosacral-radicular-pain/2024-08-04T13:22:34-07:00https://new.semnurpharma.com/2022/05/05/results-from-a-pivotal-phase-3-db-r-placebo-controlled-multicenter-trial-of-sp-102-a-novel-dexamethasone-injectable-formulation-for-the-treatment-of-patients-with-lumbosacral-radiculopathy-scia/2024-08-01T16:05:27-07:00https://new.semnurpharma.com/2023/11/02/scilex-holding-company-announces-positive-type-c-meeting-with-the-fda-and-reaches-agreement-on-path-forward-to-file-an-nda-for-sp-102-semdexatm-in-lumbosacral-radicular-pain-sciatica/2024-08-13T10:16:07-07:00https://new.semnurpharma.com/2022/03/18/scilex-holding-company-a-majority-owned-subsidiary-of-sorrento-therapeutics-inc-announces-final-results-for-sp-102-semdexa-efficacy-and-safety-from-its-pivotal-phase-3-clinical-trial-pr/2024-08-13T10:16:31-07:00https://new.semnurpharma.com/2021/12/09/scilex-holding-company-a-sorrento-therapeutics-inc-subsidiary-announces-highly-significant-positive-top-line-results-from-its-phase-3-non-opioid-injectable-sp-102-semdexa-pivotal-trial/2024-08-13T10:16:37-07:00https://new.semnurpharma.com/2020/07/20/scilex-holding-company-a-sorrento-company-announces-complete-enrollment-on-non-opioid-injectable-sp-102-semdexa-phase-3-pivotal-trial-c-l-e-a-r-program-for-sciatica-pain-management/2024-08-13T10:16:46-07:00https://new.semnurpharma.com/2020/10/07/scilex-holding-company-a-subsidiary-of-sorrento-therapeutics-announces-continuous-sales-growth-in-ztlido-and-expects-to-complete-enrollment-on-its-sp-102-semdexa-phase-3-pivotal-tri/2024-08-13T10:16:42-07:00https://new.semnurpharma.com/2021/05/05/repeat-epidural-injections-of-sp-102dexamethasone-sodium-phosphate-injectablegel-in-subjects-with-lumbosacral-radiculopathy/2024-08-13T10:18:22-07:00https://new.semnurpharma.com/2022/07/12/the-pharmacokinetics-andpharmacodynamics-of-dexamethasonefollowing-epidural-sp-102-orintravenous-dexamethasone-sodiumphosphate-injection-in-subjects-withlumbosacral-radicular-pain/2024-08-13T10:18:14-07:00https://new.semnurpharma.com/2024/08/07/henry-ji-phd-executive-chairman/2026-03-17T13:25:28-07:00https://new.semnurpharma.com/2024/09/03/news-and-events/2024-09-03T09:59:04-07:00https://new.semnurpharma.com/2025/09/26/dormanfollowwill/2025-09-26T13:01:25-07:00https://new.semnurpharma.com/2025/09/26/alexanderwu/2025-09-26T13:01:45-07:00https://new.semnurpharma.com/2025/09/26/jaychun/2025-09-26T13:02:03-07:00https://new.semnurpharma.com/2025/09/26/henry-ji-phd/2026-03-17T13:24:42-07:00